Latest Breaking News On - Pietro bersani - Page 4 : vimarsana.com

Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer – IT Business Net

Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesBeverly hillsArash gabayanLinda phelan dysonSharon gabayanAfshin eli gabayanPietro bersaniKiromic biopharmaTirtht patelBeverly hills cancer centerCorporate communicationsCompany deltacelRadiation oncologist at beverly hills cancer centerPrincipal investigator at beverly hills cancer centerKiromic biopharma incSecurities exchange

Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer

Initial Tolerability and Safety Data from First Patient Expected by Year-End, with Preliminary Efficacy Results by End of January 2024 .

United statesBeverly hillsArash gabayanAfshin eli gabayanKiromic biopharmaPietro bersaniKiromic biopharma incSecurities exchangeRadiation oncologist at beverly hills cancer centerCompany deltacelBeverly hills cancer centerPrincipal investigator at beverly hills cancer centerChief executive officerHills cancer centerMedical oncologistMedical director

Kiromic BioPharma Announces Uplisting to OTCQB Market

Kiromic BioPharma Announces Uplisting to OTCQB Market
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesPietro bersaniKiromic biopharmaSecurities exchangeGroup incExchange commissionKiromic biopharma incBiopharma announces uplistingPink marketVenture marketChief executive officerGamma deltat cellsSecurities exchange actAnnual report

Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center

HOUSTON (BUSINESS WIRE) Nov 9, 2023

Beverly hillsUnited statesKiromic biopharmaLinda phelan dysonTirtht patelPietro bersaniSecurities exchangeCorporate communicationsKiromic biopharma incBeverly hills cancer centerGamma deltat cellPatients with stageChief executive officerHills cancer centerGamma deltat cellsSecurities exchange act

Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement

HOUSTON, October 23, 2023 Kiromic BioPharma, Inc. (OTC PINK: KRBP) ("Kiromic" or the "Company"), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the execution of a clinical trial agreement with Beverly Hills Cancer Center (BHCC) to conduct its Deltacel-01 Phase 1 Study. Pursuant to the agreement, BHCC, one of Southern California’s esteem

United statesBeverly hillsKiromic biopharmaLinda phelan dysonPietro bersaniAfshin eli gabayanCorporate communicationsBeverly hills cancer centerKiromic biopharma incPrincipal investigator at beverly hills cancer centerSecurities exchangeGeffen school of medicineSouthern californiaGamma deltat cellMedical directorPrincipal investigator